Blair William & Co. IL Trims Stock Holdings in TransMedics Group, Inc. $TMDX

Blair William & Co. IL reduced its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 8.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 68,487 shares of the company’s stock after selling 6,508 shares during the period. Blair William & Co. IL owned approximately 0.20% of TransMedics Group worth $9,178,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMDX. OneDigital Investment Advisors LLC boosted its position in shares of TransMedics Group by 52.6% during the first quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after buying an additional 2,065 shares during the period. Principal Financial Group Inc. grew its position in TransMedics Group by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock valued at $13,350,000 after acquiring an additional 5,480 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in TransMedics Group in the 1st quarter valued at about $291,000. New York State Teachers Retirement System increased its stake in TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock worth $1,477,000 after buying an additional 14,200 shares during the period. Finally, Peregrine Capital Management LLC increased its stake in TransMedics Group by 3.4% during the 1st quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company’s stock worth $4,601,000 after buying an additional 2,250 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TMDX. Morgan Stanley increased their price objective on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Stifel Nicolaus initiated coverage on TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 price objective on the stock. Evercore ISI initiated coverage on TransMedics Group in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price objective for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday. Finally, Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $125.40.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $107.29 on Friday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $145.50. The firm has a market capitalization of $3.66 billion, a PE ratio of 55.59 and a beta of 2.08. The stock’s 50-day simple moving average is $117.21 and its 200-day simple moving average is $112.11.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. The business’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the company earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.